全文获取类型
收费全文 | 1526篇 |
免费 | 74篇 |
国内免费 | 5篇 |
专业分类
耳鼻咽喉 | 18篇 |
儿科学 | 72篇 |
妇产科学 | 14篇 |
基础医学 | 222篇 |
口腔科学 | 32篇 |
临床医学 | 123篇 |
内科学 | 431篇 |
皮肤病学 | 46篇 |
神经病学 | 60篇 |
特种医学 | 64篇 |
外科学 | 201篇 |
综合类 | 89篇 |
预防医学 | 77篇 |
眼科学 | 21篇 |
药学 | 56篇 |
中国医学 | 3篇 |
肿瘤学 | 76篇 |
出版年
2023年 | 14篇 |
2022年 | 12篇 |
2021年 | 49篇 |
2020年 | 32篇 |
2019年 | 30篇 |
2018年 | 33篇 |
2017年 | 30篇 |
2016年 | 23篇 |
2015年 | 41篇 |
2014年 | 41篇 |
2013年 | 54篇 |
2012年 | 87篇 |
2011年 | 70篇 |
2010年 | 42篇 |
2009年 | 35篇 |
2008年 | 70篇 |
2007年 | 81篇 |
2006年 | 68篇 |
2005年 | 65篇 |
2004年 | 89篇 |
2003年 | 83篇 |
2002年 | 59篇 |
2001年 | 60篇 |
2000年 | 44篇 |
1999年 | 49篇 |
1998年 | 29篇 |
1997年 | 17篇 |
1996年 | 27篇 |
1995年 | 18篇 |
1994年 | 8篇 |
1993年 | 10篇 |
1992年 | 12篇 |
1991年 | 23篇 |
1990年 | 16篇 |
1989年 | 22篇 |
1988年 | 9篇 |
1987年 | 20篇 |
1986年 | 16篇 |
1985年 | 19篇 |
1984年 | 11篇 |
1983年 | 5篇 |
1982年 | 6篇 |
1981年 | 6篇 |
1980年 | 8篇 |
1979年 | 11篇 |
1977年 | 6篇 |
1974年 | 5篇 |
1971年 | 4篇 |
1970年 | 5篇 |
1945年 | 4篇 |
排序方式: 共有1605条查询结果,搜索用时 19 毫秒
1.
2.
3.
Isolation of Stomatococcus mucilaginosus from drug user with endocarditis. 总被引:4,自引:4,他引:0 下载免费PDF全文
P E Coudron S M Markowitz L B Mohanty P F Schatzki J M Payne 《Journal of clinical microbiology》1987,25(8):1359-1363
Stomatococcus mucilaginosus was isolated from the blood of a patient with endocarditis and a past history of drug abuse and aortic valve replacement. At autopsy, Gram stain of the aortic valve revealed gram-positive cocci. Our isolate was atypical for S. mucilaginosus in that colonies were nonmucoid and nonadherent to agar surfaces. Cellular capsules were demonstrated by light and electron microscopy. Phenotypic characteristics identified by conventional methods as well as profile numbers obtained by using two commercial identification systems for staphylococci, the API Staph-Ident and the dms Staph Trac, are presented. Practical tests that differentiate S. mucilaginosus from the genera Micrococcus and Staphylococcus include growth on nutrient agar containing salt and lysostaphin susceptibility. Additional tests that helped differentiate our isolate from group D streptococci included hydrolysis of L-pyrrolidonyl-beta-naphthylamide and streptococcal serogrouping. 相似文献
4.
A. Ravikumar S. Mohanty R. P. Vatsanath S. Raghunandhan 《Indian journal of otolaryngology and head and neck surgery》2004,56(4):317-320
The co-existence of fungal elements in allergic nasal Polyposis, has given rise to a distinct clinical entity known as ‘Allergic
fungal sinusitis ’ (AF’S). Many a time, these fungal elements may not be diagnosed pre-operatively by routine diagnostic nasal
endoscopy or CT scan of paranasal sinuses, due to the florid presentation of nasal polyps, which usually obscure the underlying
fungal pathology. The diagnosis is often made intra-operatively. The post-operative confirmation of AFS is by histopathology,
fungal smear, fungal culture, allergic murin study and fungal specific IgE titres. We report a series often such cases done
in our institution, which highlight that AFS should be considered as a differential diagnosis in Sinonasal Polyposis cases,
for their effective management. 相似文献
5.
A. Satish Chandra Sanjeev Mohanty 《Indian journal of otolaryngology and head and neck surgery》2007,59(1):43-44
Role of Embolisation in preoperative management of Nasopharyngeal angiofibroma is well established in present day therapeutic
modalities. An improvised technique i.e., subselective embolisation has been provided by Interventional radiologists to fortify
the therapeutic results. This study compares the final outcome of seven cases, four of which were embolised pre operatively.
Each case was dealt with varying surgical approaches. 相似文献
6.
7.
Enhancement of cisplatin sensitivity of cisplatin-resistant human cervical carcinoma cells by bryostatin 1. 总被引:2,自引:0,他引:2
PURPOSE: Bryostatin 1, a unique protein kinase C (PKC) activator, is already in the clinical trials. An understanding of complex regulation of PKC by bryostatin 1 is essential for effective use of bryostatin 1 in the clinic. We have previously shown that the ability of bryostatin 1 to enhance cisplatin sensitivity correlated with its ability to down-regulate PKCdelta in HeLa cells. We have investigated how bryostatin 1 influences PKCdelta regulation in cisplatin-resistant HeLa (HeLa/CP) cells, and if bryostatin 1 could be used to reverse cisplatin resistance. EXPERIMENTAL DESIGN: Phorbol 12,13-dibutyrate (PDBu), bryostatin 1, and small interfering RNA were used to manipulate PKC level/activation status. Cell death was monitored by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay, Annexin V dye-binding assay, and analysis of hypodiploid peak in a flow cytometer. RESULTS: Bryostatin 1 elicited a biphasic concentration response on PKCdelta down-regulation and cisplatin-induced cell death in HeLa/CP cells; the maximum effect was achieved with 1 nmol/L bryostatin 1. Down-regulation of PKCalpha increased with increasing concentrations of bryostatin 1. PDBu induced down-regulation of PKCalpha in HeLa and HeLa/CP cells but it had little effect on PKCdelta down-regulation in HeLa/CP cells. However, both PDBu and bryostatin 1 enhanced the sensitivity of HeLa/CP cells to cisplatin. Knockdown of PKCdelta by small interfering RNA inhibited cisplatin-induced apoptosis but knockdown of PKCalpha enhanced cisplatin-induced cell death. CONCLUSIONS: These results suggest that although PKCdelta acts as a proapoptotic protein, full-length PKCdelta may inhibit cisplatin-induced cell death. Thus, persistent activation/down-regulation of PKCdelta by bryostatin 1 was associated with cisplatin sensitization. Furthermore, PKCalpha acts as an antiapoptotic protein and down-regulation of PKCalpha by PDBu was associated with cellular sensitization to cisplatin. 相似文献
8.
9.
10.
Raina V Sharma A Deo SV Shukla NK Mohanty BK Goel A Rath GK 《The Journal of the Association of Physicians of India》1998,46(11):926-929
Results of primary surgery with or without locoregional radiotherapy (LRRT) are poor in stage III (T4b, NO-2, M0) breast cancer. Combination of mitoxantrone, mitomycin-c and methotrexate (MMM) has been reported to be as efficacious as doxorubicin based protocols with advantages of reduced nausea, vomiting, alopecia and cardiotoxicity. We tested MMM chemotherapy with LRRT and surgery in locally advanced breast cancer (LABC) with a view to assess response, survival, breast conservation, cost and toxicity. Fifty two previously untreated patients were given Mitoxantrone: 8 mg/m sq by infusion on days 1 and 21, Mitomycin-C: 8 mg/m sq by infusion on day 1 and Methotrexate: 35 mg/m sq i.v. on days 1 and 21. Cycles were repeated every 42 days. After 3 cycles LRRT was given if lump reduced to less than 2 cms. Otherwise patients were subjected to modified radical mastectomy (MRM) or radical mastectomy (RM). Following this 3 more cycles of chemotherapy were given. Patients with soft tissue, skin or heavy nodal involvement also received LRRT. Tamoxifen 20 mg daily was prescribed at the end of chemotherapy to postmenopausal patients. Complete/partial responses were seen in 5 and 26 patients, respectively after chemotherapy giving an overall response of 59.5%. Twenty four patients each had LRRT and MRM/RM. Responses could be significantly enhanced by LRRT/and or surgery. Nineteen out of 25 relapses were at distant sites. Breast conservation was achieved in 24/52 (46%) patients. Three year disease free and overall survival was 54% and 65%, respectively. There was 1 toxic death. Severe prolonged myelosuppresion was seen in those who also received LRRT. Mucositis, alopecia, nausea and vomiting were minor problems. Overall, combination was less expensive than doxorubicin based protocols. 相似文献